# CuroGene Life Sciences Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curogene-life-sciences-co

- Industry: Pharmaceuticals
- Headquarters: Cheongju, South Korea
- Website: www.curogenels.com
- Total disclosed funding: $5M
- Latest round: Series A (Dec 5, 2019)
- Investors on record: 4

## About

Based in Cheongju-si, Cheongbuk-do, South Korea and founded in 2018, CuroGene Life Sciences Co., Ltd. is a pharmaceutical company founded in Korea aiming to be the partner for patients with eye disorders through developments in genetic biologics. In 2019, the company opened a research and development center in Seoul and founded CuroVision Co., Ltd. in USA. The company secured new drug candidates for retinal vascular disease through close collaboration research with professors in the field of genetics and cell therapy and ophthalmologists at universities.

The company manufactures a gene therapeutics pipeline for curing eye disorders namely, CRG-101, CRG-102, CRG-201 and CRG-202.

## Funding rounds

- Series A, Dec 5, 2019, $5M — KB Securities, ROI Investment Partners, Laguna Investment, DS Asset Management

## Investors

- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series A
- ROI Investment Partners (https://capitalatlas.ai/funds/roi-investment-partners) — Series A
- Laguna Investment (https://capitalatlas.ai/funds/laguna-investment) — Series A
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series A